Helix BioPharma Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HBP.TO research report →
Price Chart
About the company
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2.
- CEO
- Thomas Mehrling
- IPO
- 1996
- Employees
- 7
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on HBP.TO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $152.76M
- P/E
- -45.45
- PEG
- -0.17
- P/S
- 0.00
- P/B
- 10.40
- EV/EBITDA
- -48.73
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -21.54%
- ROIC
- -21.65%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-10,000+28.6%
- Op Income
- $-5,425,000
- Net Income
- $-5,205,000+43.8%
- EPS
- $-0.09+55.5%
- OCF Growth
- +26.6%
- FCF Growth
- +26.8%
- 52W High
- $5.40
- 52W Low
- $1.10
- 50D MA
- $1.52
- 200D MA
- $1.88
- Beta
- -0.35
- RSI (14)
- 83
- Avg Volume
- 1.32K
No earnings-call transcripts are available for HBP.TO yet.
- Free Float
- 71.1%
- Shares Outstanding
- 76.38M
- Float Shares
- 54.27M
of shares held by institutions
1 13F filers
Our HBP.TO coverage
Recent articles, reports, and earnings notes.
No research on HBP.TO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HBP.TO report →